Biotech Co.*

Pharma Co.


Terms/Details (Date)

Ambrx Inc.*

CMC Biopharmaceuticals A/S (Denmark)

Deal for the manufacture of an Ambrx pegylated recom- binant growth hormone

CMC will manufacture the product for use in human clinical studies; terms of the deal were not disclosed (6/3)

Antisoma plc

Heraeus GmbH (Germany)

Heraeus will provide supplies of Antisoma's AS1410 for clinical trials

Trials of the telomere-targeting agent are expected to begin in 2006; terms of the deal were not disclosed (6/2)


Undisclosed U.S.-based company

Deal for the manufacture of large-scale quantities of BioSante's calcium phosphate-based nanotechnology

The product will be tested by another company to develop an oral formulation of a marketed injectable protein product; terms were not disclosed (5/3)


Dipsi Industrie (France)

Dipsi will distribute the Dynaflow System for ion channel drug discovery in France

Dipsi will provide sales and technical support to the French market under undisclosed terms (5/17)

Codexis Inc.*

Shasun Chemicals and Drugs Ltd. (India)

Manufacturing and supply agreement for a pharmaceutical intermediate for a generic drug

Shasun will manufacture the compound and Codexis will market it worldwide to the generic industry; Codexis will provide the biocatalyst for use in production, and they will share profits on sales (5/11)


Inter Medical Co. Ltd. (Japan)

Inter Medical will distribute CombiMatrix's CustomArray microarray products in Japan

Terms of the nonexclusive distribution deal were not disclosed (5/2)

Genetics Inc.

Boehringer Ingelheim Austria GmbH

Deal covering manufacturing of VEGF-2 plasmid DNA for Phase III trials and future commercial use

BI will manufacture Corautus' product under undisclosed terms (5/16)

Exiqon A/S*

Roche Diagnostics (Switzerland)

Roche was named sole distributor of Exiqon's ProbeLibrary Kits

The kits are used for gene expression analysis and target validation of microarray experiments; terms were not disclosed (5/17)

InSite Vision

Unnamed company

They signed a deal for the long-term supply of azithromycin

Azithromycin is the active drug in InSite's AzaSite ocular anti-infective product, which is in Phase III trials (5/18)

Novavax Inc.

Cardinal Health Inc.

They restructured agreement for the manufacture of Novavax's Estrasorb

Novavax will manufacture the topical emulsion for estrogen therapy; Cardinal will take care of fill-finish operations; the move is expected to reduce Novavax's manufacturing costs (5/9)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange.